Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer

[1]  A. Oza,et al.  Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Gygi,et al.  DAGBagM: learning directed acyclic graphs of mixed variables with an application to identify protein biomarkers for treatment response in ovarian cancer , 2022, BMC Bioinformatics.

[3]  M. Lanuti,et al.  Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes. , 2022, Cancer cell.

[4]  A. Ashworth,et al.  Validation of anti-correlated TGFβ signaling and alternative end-joining DNA repair signatures that predict response to genotoxic cancer therapy. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  Jeffrey R. Whiteaker,et al.  Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer , 2021, Cell reports. Medicine.

[6]  M. Barcellos-Hoff,et al.  Exploiting Canonical TGFβ Signaling in Cancer Treatment , 2021, Molecular Cancer Therapeutics.

[7]  Sara R. Savage,et al.  A highly annotated database of genes associated with platinum resistance in cancer , 2021, Oncogene.

[8]  B. Karlan,et al.  PARP inhibitor maintenance for primary ovarian cancer - A missed opportunity for precision medicine. , 2021, Gynecologic oncology.

[9]  Dana R. Valley,et al.  A proteogenomic portrait of lung squamous cell carcinoma , 2021, Cell.

[10]  David R. Jones,et al.  Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients , 2021, Cell.

[11]  Jeffrey R. Whiteaker,et al.  Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues. , 2021, Clinical chemistry.

[12]  F. Ahammad,et al.  Transporter associated with antigen processing 1 (TAP1) expression and prognostic analysis in breast, lung, liver, and ovarian cancer , 2021, Journal of Molecular Medicine.

[13]  O. Schilling,et al.  A Systematic Evaluation of Semispecific Peptide Search Parameter Enables Identification of Previously Undescribed N-Terminal Peptides and Conserved Proteolytic Processing in Cancer Cell Lines , 2021, Proteomes.

[14]  N. Almog,et al.  Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. , 2021, Cancer cell.

[15]  David C. Smith,et al.  Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors , 2021, JAMA oncology.

[16]  Jeffrey R. Whiteaker,et al.  Loss of TGFβ signaling increases alternative end-joining DNA repair that sensitizes to genotoxic therapies across cancer types , 2021, Science Translational Medicine.

[17]  Anna Luisa Di Stefano,et al.  Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities , 2021, Nature Cancer.

[18]  Guo Ci Teo,et al.  Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer , 2020, Cell.

[19]  A. Dispenzieri,et al.  Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 Samples. , 2020, Mayo Clinic proceedings.

[20]  Fengchao Yu,et al.  Identification of modified peptides using localization-aware open search , 2020, Nature Communications.

[21]  Martin T. Morgan,et al.  Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma , 2020, Cancer Research.

[22]  J. Tabernero,et al.  Clinical development of therapies targeting TGFβ: current knowledge and future perspectives. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Samuel H. Payne,et al.  Crowdsourced Assessment of the of Predictability of Cancer Protein and Phosphoprotein Levels from Genomics and Transcriptomics. , 2020, Cell systems.

[24]  Alexey I. Nesvizhskii,et al.  Philosopher: a versatile toolkit for shotgun proteomics data analysis , 2020, Nature Methods.

[25]  Francesca Petralia,et al.  ProTrack: An Interactive Multi‐Omics Data Browser for Proteogenomic Studies , 2020, Proteomics.

[26]  A. Oza,et al.  Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer , 2020, Cancers.

[27]  Alexey I. Nesvizhskii,et al.  Quantitative proteomic landscape of metaplastic breast carcinoma pathological subtypes and their relationship to triple-negative tumors , 2020, Nature Communications.

[28]  L. D. Miller,et al.  Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response , 2020, Journal for ImmunoTherapy of Cancer.

[29]  Matthew H Bailey,et al.  Interpreting pathways to discover cancer driver genes with Moonlight , 2020, Nature Communications.

[30]  F. Marmé,et al.  Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. , 2019, The New England journal of medicine.

[31]  N. Hacohen,et al.  SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint , 2019, bioRxiv.

[32]  Guo Ci Teo,et al.  Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma , 2019, Cell.

[33]  B. Monk,et al.  Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. , 2019, The New England journal of medicine.

[34]  Kevin J. Gleason,et al.  Insights into Impact of DNA Copy Number Alteration and Methylation on the Proteogenomic Landscape of Human Ovarian Cancer via a Multi-omics Integrative Analysis. , 2019, Molecular & cellular proteomics : MCP.

[35]  Catherine J. Wu,et al.  SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer , 2019, Cancer Immunology Research.

[36]  J. Weinstein,et al.  Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. , 2019, Cell reports.

[37]  Eric W. Deutsch,et al.  PTMProphet: Fast and Accurate Mass Modification Localization for the Trans-Proteomic Pipeline , 2019, bioRxiv.

[38]  G. Mills,et al.  Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference , 2019, Cancer.

[39]  Paul J. Hoffman,et al.  Comprehensive Integration of Single-Cell Data , 2018, Cell.

[40]  Bing Zhang,et al.  Graph Algorithms for Condensing and Consolidating Gene Set Analysis Results* , 2019, Molecular & Cellular Proteomics.

[41]  Ayesha Obaid,et al.  Formal model of the interplay between TGFβ1 and MMP-9 and their dynamics in hepatocellular carcinoma. , 2019, Mathematical biosciences and engineering : MBE.

[42]  M. Parmar,et al.  Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. , 2018, The Lancet. Oncology.

[43]  M. Gore,et al.  Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer , 2018, BMC Cancer.

[44]  Jeffrey R. Whiteaker,et al.  Clinical potential of mass spectrometry-based proteogenomics , 2018, Nature Reviews Clinical Oncology.

[45]  A. Oza,et al.  Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors , 2018, Genome Medicine.

[46]  Gabe S. Sonke,et al.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.

[47]  Obi L. Griffith,et al.  Standard operating procedure for somatic variant refinement of sequencing data with paired tumor and normal samples , 2018, Genetics in Medicine.

[48]  J. Murnane,et al.  Subjugation of TGFβ Signaling by Human Papilloma Virus in Head and Neck Squamous Cell Carcinoma Shifts DNA Repair from Homologous Recombination to Alternative End Joining , 2018, Clinical Cancer Research.

[49]  Aviad Tsherniak,et al.  Mutational processes shape the landscape of TP53 mutations in human cancer , 2018, Nature Genetics.

[50]  Christopher T. Saunders,et al.  Strelka2: fast and accurate calling of germline and somatic variants , 2018, Nature Methods.

[51]  Gregory M. Chen,et al.  Consensus on Molecular Subtypes of High-Grade Serous Ovarian Carcinoma , 2018, Clinical Cancer Research.

[52]  Nicolai J. Birkbak,et al.  Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer , 2018, npj Breast Cancer.

[53]  Li Wang,et al.  A new method for constructing tumor specific gene co-expression networks based on samples with tumor purity heterogeneity , 2018, Bioinform..

[54]  Nancy R. Zhang,et al.  Bulk tissue cell type deconvolution with multi-subject single-cell expression reference , 2018, Nature Communications.

[55]  Michael J MacCoss,et al.  Panorama Public: A Public Repository for Quantitative Data Sets Processed in Skyline* , 2018, Molecular & Cellular Proteomics.

[56]  Yeting Zhang,et al.  Functional equivalence of genome sequencing analysis pipelines enables harmonized variant calling across human genetics projects , 2018, Nature Communications.

[57]  J. Espinosa,et al.  Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activity , 2017, Genome research.

[58]  C. Lindskog,et al.  A pathology atlas of the human cancer transcriptome , 2017, Science.

[59]  Selim Kalayci,et al.  iCAVE: an open source tool for visualizing biomolecular networks in 3D, stereoscopic 3D and immersive 3D , 2017, GigaScience.

[60]  Alexey I Nesvizhskii,et al.  MSFragger: ultrafast and comprehensive peptide identification in shotgun proteomics , 2017, Nature Methods.

[61]  A. Butte,et al.  xCell: digitally portraying the tissue cellular heterogeneity landscape , 2017, bioRxiv.

[62]  C. Prives,et al.  Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53. , 2017, Cold Spring Harbor perspectives in medicine.

[63]  J. Olson,et al.  Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance) , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  Kun Yu,et al.  PureCN: copy number calling and SNV classification using targeted short read sequencing , 2016, Source Code for Biology and Medicine.

[65]  Jüergen Cox,et al.  The MaxQuant computational platform for mass spectrometry-based shotgun proteomics , 2016, Nature Protocols.

[66]  Jeffrey R. Whiteaker,et al.  Optimized Protocol for Quantitative Multiple Reaction Monitoring-Based Proteomic Analysis of Formalin-Fixed, Paraffin-Embedded Tissues. , 2016, Journal of proteome research.

[67]  V. Syed,et al.  TGF‐β Signaling in Cancer , 2016, Journal of cellular biochemistry.

[68]  Ronald J. Moore,et al.  Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer , 2016, Cell.

[69]  H. Fiegl,et al.  Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancer , 2016, Oncotarget.

[70]  Lior Pachter,et al.  Near-optimal probabilistic RNA-seq quantification , 2016, Nature Biotechnology.

[71]  Eric Talevich,et al.  CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing , 2016, PLoS Comput. Biol..

[72]  B. Bay,et al.  Transglutaminase 2 contributes to a TP53-induced autophagy program to prevent oncogenic transformation , 2016, eLife.

[73]  Tianqi Chen,et al.  XGBoost: A Scalable Tree Boosting System , 2016, KDD.

[74]  F. Cunningham,et al.  The Ensembl Variant Effect Predictor , 2016, bioRxiv.

[75]  Brent S. Pedersen,et al.  Vcfanno: fast, flexible annotation of genetic variants , 2016, bioRxiv.

[76]  Francesca Petralia,et al.  New Method for Joint Network Analysis Reveals Common and Different Coexpression Patterns among Genes and Proteins in Breast Cancer , 2016, Journal of proteome research.

[77]  Gianluca Bontempi,et al.  TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data , 2015, Nucleic acids research.

[78]  Heng Li,et al.  Minimap and miniasm: fast mapping and de novo assembly for noisy long sequences , 2015, Bioinform..

[79]  Matthew Chambers,et al.  Correcting systematic bias and instrument measurement drift with mzRefinery , 2015, Bioinform..

[80]  D. Meyre,et al.  From big data analysis to personalized medicine for all: challenges and opportunities , 2015, BMC Medical Genomics.

[81]  J. Abraham,et al.  Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer , 2015, International Journal of Gynecologic Cancer.

[82]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[83]  Joshy George,et al.  Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.

[84]  Jérôme Cros,et al.  Targeting the TGFβ pathway for cancer therapy. , 2015, Pharmacology & therapeutics.

[85]  Bin Zhang,et al.  PhosphoSitePlus, 2014: mutations, PTMs and recalibrations , 2014, Nucleic Acids Res..

[86]  Pavel A. Pevzner,et al.  Universal database search tool for proteomics , 2014, Nature Communications.

[87]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[88]  Tao Huang,et al.  MODMatcher: Multi-Omics Data Matcher for Integrative Genomic Analysis , 2014, PLoS Comput. Biol..

[89]  Andrew N Hoofnagle,et al.  From lost in translation to paradise found: enabling protein biomarker method transfer by mass spectrometry. , 2014, Clinical chemistry.

[90]  A. Tutt,et al.  Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers , 2014, Breast Cancer Research.

[91]  Ronald J Moore,et al.  Ischemia in Tumors Induces Early and Sustained Phosphorylation Changes in Stress Kinase Pathways but Does Not Affect Global Protein Levels* , 2014, Molecular & Cellular Proteomics.

[92]  Guillem Rigaill,et al.  Performance evaluation of DNA copy number segmentation methods , 2014, Briefings Bioinform..

[93]  W. Wiedemeyer,et al.  Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System , 2014, Front. Oncol..

[94]  Susan E. Abbatiello,et al.  Targeted Peptide Measurements in Biology and Medicine: Best Practices for Mass Spectrometry-based Assay Development Using a Fit-for-Purpose Approach* , 2014, Molecular & Cellular Proteomics.

[95]  Sheena M. Scroggins,et al.  Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas , 2013, Clinical Cancer Research.

[96]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[97]  Jiri Bartek,et al.  Replication stress links structural and numerical cancer chromosomal instability , 2013, Nature.

[98]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[99]  K. Cibulskis,et al.  Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. , 2012, The Journal of clinical investigation.

[100]  J. Massagué.  TGFβ signalling in context , 2012, Nature Reviews Molecular Cell Biology.

[101]  John Quackenbush,et al.  Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome , 2012, Clinical Cancer Research.

[102]  P. Altevogt,et al.  L1CAM , 2012, Cell adhesion & migration.

[103]  P. Altevogt,et al.  Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-κB activation. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[104]  A. McKenna,et al.  Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.

[105]  Kenneth P. Nephew,et al.  Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.

[106]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[107]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[108]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[109]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[110]  Xulei Tang,et al.  Metformin reverses the deleterious effects of high glucose on osteoblast function. , 2010, Journal of diabetes and its complications.

[111]  Matthew D. Wilkerson,et al.  ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..

[112]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[113]  D. Ginsberg,et al.  p53 and E2f: partners in life and death , 2009, Nature Reviews Cancer.

[114]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[115]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[116]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[117]  Joshua N. Adkins,et al.  MASIC: A software program for fast quantitation and flexible visualization of chromatographic profiles from detected LC-MS(/MS) features , 2008, Comput. Biol. Chem..

[118]  Andrei V Bakin,et al.  TAK1 is required for TGF-β1-mediated regulation of matrix metalloproteinase-9 and metastasis , 2007, Oncogene.

[119]  V. Kaklamani,et al.  A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX , 2006, Expert review of molecular diagnostics.

[120]  S. Jakowlew.  Transforming growth factor-β in cancer and metastasis , 2006, Cancer and Metastasis Reviews.

[121]  A. Levine,et al.  The coordinate regulation of the p53 and mTOR pathways in cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[122]  Emilie Lebarbier,et al.  Detecting multiple change-points in the mean of Gaussian process by model selection , 2005, Signal Process..

[123]  R. Aebersold,et al.  A statistical model for identifying proteins by tandem mass spectrometry. , 2003, Analytical chemistry.

[124]  F. Muggia.  Sequential single agents as first-line chemotherapy for ovarian cancer: a strategy derived from the results of GOG-132 , 2003, International Journal of Gynecologic Cancer.

[125]  R. L. Baldwin,et al.  Improved survival in women with BRCA‐associated ovarian carcinoma , 2003, Cancer.

[126]  L. Tretter,et al.  Quantitative relationship between inhibition of respiratory complexes and formation of reactive oxygen species in isolated nerve terminals , 2002, Journal of neurochemistry.

[127]  Alexey I Nesvizhskii,et al.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. , 2002, Analytical chemistry.

[128]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[129]  D. Sheppard,et al.  The integrin αvβ8 mediates epithelial homeostasis through MT1-MMP–dependent activation of TGF-β1 , 2002, The Journal of cell biology.

[130]  G. Núñez,et al.  Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. , 1997, Blood.

[131]  C. Rudin,et al.  Expression of bcl-xL can confer a multidrug resistance phenotype. , 1995, Blood.

[132]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.

[133]  S. Cannistra.  Cancer of the ovary. , 1993, The New England journal of medicine.

[134]  S. Rubin,et al.  Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  R. Bellman.  On the approximation of curves by line segments using dynamic programming , 1961, CACM.

[136]  OUP accepted manuscript , 2021, American Journal of Clinical Pathology.

[137]  A. Hoofnagle,et al.  More sensitivity is always better: Measuring sub-clinical levels of serum thyroglobulin on a µLC–MS/MS system , 2020 .

[138]  Ash A. Alizadeh,et al.  Profiling Tumor Infiltrating Immune Cells with CIBERSORT. , 2018, Methods in molecular biology.

[139]  Thomas D. Wu,et al.  GMAP and GSNAP for Genomic Sequence Alignment: Enhancements to Speed, Accuracy, and Functionality , 2016, Statistical Genomics.

[140]  S. Grossman,et al.  Mechanisms of mutant p53 stabilization in cancer. , 2014, Sub-cellular biochemistry.

[141]  J. Krstić,et al.  Review Article Transforming Growth Factor-beta and Matrix Metalloproteinases: Functional Interactions in Tumor Stroma-infiltrating Myeloid Cells , 2022 .

[142]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[143]  Claude-Alain H. Roten,et al.  Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..

[144]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[145]  L. Breiman.  Random Forests , 2001, Machine Learning.

[146]  Brendan MacLean,et al.  Bioinformatics Applications Note Gene Expression Skyline: an Open Source Document Editor for Creating and Analyzing Targeted Proteomics Experiments , 2022 .